Introduction
Methods
Participants
Assessment of symptoms in patients with MDD
Blood samples and physical measurements
Data analysis and statistics
Results
Variables | ||
---|---|---|
Agea | year | 42.4 ± 14.7 |
Body mass indexa | kg/m2 | 24.2 ± 3.1 |
Smoker / non smoker | n | 13 / 41 |
HAM-Da | 19.3 ± 7.0 | |
GAFa | 32.4 ± 7.6 | |
Duration of illnessa | year | 6.2 ± 7.9 |
No. depressive episodesa | 1.7 ± 1.1 | |
Antidepressant use | n (%) | 39 (72.2) |
TCA | n (%) | 1 (1.8) |
SSRI | n (%) | 27 (50.0) |
SNRI | n (%) | 7 (13.0) |
NaSSA | n (%) | 4 (7.4) |
Imipramine equivalencea | mg/day | 110.7 ± 95.4 |
Benzodiazepine use | n (%) | 17 (31.5) |
Severity/course specifier at first medical examinationenzodiazepine use | ||
Mild | n (%) | 14 (25.9) |
Moderate | n (%) | 29 (53.7) |
Severe | n (%) | 5 (9.2) |
With psychotic features | n (%) | 3 (5.6) |
In partial remission | n (%) | 3 (5.6) |
Variables | MDD1 | Control | P value |
---|---|---|---|
Number | 54 | 37 | – |
Age (year)a | 42.4 ± 14.7 | 39.4 ± 7.0 | P = 0.187† |
Body mass index (kg/m2)a | 24.2 ± 3.1 | 24.0 ± 3.5 | P = 0.661† |
Smoker/non smoker | 13 / 41 | 5 / 32 | P = 0.214‡ |
HbA1c (%)a4 | 5.4 ± 0.5 | 5.4 ± 0.8 | P = 0.970† |
Cortisol (μg/dl)a | 12.1 ± 4.8 | 11.1 ± 3.0 | P = 0.191† |
DHEAS (μg/dl)a2 | 227.9 ± 108.4 | 307.4 ± 131.2 | P = 0.002† |
Cortisol / DHEAS ratioa | 0.07 ± 0.05 | 0.04 ± 0.02 | P = 0.001† |
IGF1 (ng/ml)a3 | 171.5 ± 61.8 | 144.1 ± 39.2 | P = 0.011† |
Testosterone (ng/ml)a | 5.0 ± 1.6 | 4.9 ± 1.6 | P = 0.709† |
Estradiol (pg/ml)a | 22.4 ± 8.4 | 26.1 ± 8.5 | P = 0.040† |
Independent Variables | Adjusted R2 | Constant | F | β | SE | P |
---|---|---|---|---|---|---|
Total mode | 0.242 | 28.827 | 17.916 | 0.000094 | ||
Estradiol | −0.424 | 0.100 |
Independent Variables | Adjusted R2 | Constant | F | β | SE | P |
---|---|---|---|---|---|---|
Total mode | 0.289 | 3.880 | 11.786 | 0.000062 | ||
Testosterone | 2.388 | 0.610 | ||||
DHEAS | 0.029 | 0.009 |